Tumour Suppressors

After a PhD in copper metabolism at the University of Utrecht (the Netherlands), I started my postdoctoral career in 2008 at the CRUK Beatson Institute in Glasgow in Karen Vousden’s lab.  I obtained a personal Rubicon fellowship from the NWO (a Dutch scientific organisation) to work on mutant p53 function in metastasis for three years. This project resulted in a publication in Cell in 2009 and allowed for an extension of my postdoctoral position on an AICR grant with Karen Vousden for two years. I continued my career with a Sir Henry Dale fellowship from the Wellcome Trust/Royal Society in 2013 at the MRC Toxicology Unit on the function of mutant p53 in chemoresistance. I received an early career award from the Biochemical Society in 2015.

Qualifications

  • PhD (2008), University of Utrecht, Department of Metabolic and Endocrine Diseases, Utrecht, the Netherlands
  • Title: Transcriptomics and molecular approaches to dissect copper metabolism and the role of COMMD proteins in cellular function

Areas of Expertise

(Mutant) p53 function, cell migration and invasion, chemoresistance, copper toxicity

Selected Publications

Aschauer L, Muller PA. (2016)
Novel targets and interaction partners of mutant p53 gain-of-function.
Biochemical Society Transactions
44(2):460-6. PubMed Abstract

Muller PA*, K. Vousden.* (2014)
Mutant p53 in cancer : New functions and therapeutic opportunites.
Cancer Cell
25(3):304-17.  PubMed Abstract *Corresponding author

Muller PA*, Trinidad AG, Caswell PT, Norman JC, Vousden KH. (2014)
Mutant p53 regulates Dicer through p63 dependent and independent mechanisms to promote an invasive phenotype.
Journal of Biological Chemistry
289(1):122-32. PubMed Abstract *Corresponding author

Tan EH, Morton JP, Timpson P, Tucci P, Melino G, Flores ER, Sansom OJ, Vousden KH, Muller PA. (2014)
Functions of TAp63 and p53 in restraining the development of metastatic cancer.
Oncogene
33(25):3325-33. PubMed Abstract

Trinidad AG, Muller PA, Cuellar J, Klejnot M, Valpuesta JM, Vousden KH. (2013)
Interaction with the CCT complex promotes protein folding and WT p53 activity.
Molecular Cell
50(6):805-17. PubMed Abstract

Muller PA, Trinidad AG, Caswell P, Noll JE, Coffill CR, Lane DP, Neilsen PM, Norman JC, Vousden KH. (2013)
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.
Oncogene
32(10):1252-65. PubMed Abstract

Muller PA, Vousden KH. (2013)
p53 mutations in cancer.
Nature Cell Biology
15(1):2-8. PubMed Abstract

Muller PA*, Coffill CR*,  Hogue KA, Cheok CF, Oh HK, Neo SP, Vousden KH, Lane DP, Blackstock WP, Gunaratne HJ. (2012)
Mutant p53 interactome reveals nardilysin as a p53R273H-specific binding  partner involved in invasion.
EMBO Reports
13(7):638-44. PubMed Abstract *joint first author

Muller PA*, Vousden KH, Norman JC.* (2011)
p53 and its mutants in tumor cell migration and invasion.
Journal of Cell Biology
192(2):209-18. PubMed Abstract *corresponding author

Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH. (2009)
Mutant p53 drives invasion by promoting integrin recycling.
Cell
139(7):1327-41. PubMed Abstract